In this interview, Flavio Ribichini and Sofie Brouwers discuss the evolving role of renal denervation in the management of hypertension. Now endorsed by major guidelines for patients with uncontrolled or resistant hypertension, the therapy is gaining wider acceptance in clinical practice.
They highlight the distinction between true resistant hypertension and uncontrolled hypertension, and stress the importance of patient selection and shared decision-making. Particular attention is given to high-risk groups, such as patients with chronic kidney disease, who may derive significant benefit.
Supported by growing evidence from long-term studies, renal denervation is presented as a safe, well-tolerated option with sustained blood pressure reduction, offering a valuable complement to medical therapy.
